X
[{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAX BioPharma Announces Key Update to its Liver Fibrosis Program ","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by MAX BioPharma
Filters
Companies By Therapeutic Area
Details:
Oxy210 was found to significantly inhibit development of fibrosis in a humanized mouse model of NASH that involves progressive inflammation, fat deposition and fibrosis in the livers of these mice.
Lead Product(s):
Oxy210
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 03, 2020